News | Stents Bioresorbable | October 15, 2015

SCAI: Bioabsorbable Stent Technologies Will Expand Options for Cardiovascular Disease Patients

Synergy and Absorb stents offer treatment for heart blockages without long-term complications of permanent stent components

SCAI, new bioabsorbable stent technologies, TCT 2015, Absorb, Synergy

Synergy stent image courtesy of Boston Scientific

October 15, 2015 — Two new advances in stent technology announced in recent days further reinforce the effectiveness of the next-generation bioabsorbable stents. Both new stents are designed to help reduce the risk of long-term complications for patients receiving a stent and will give interventional cardiologists more options in the care of cardiovascular patients. 

One-year results from the ABSORB III trial were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2015 in San Francisco. The study met its primary endpoint, demonstrating the Absorb stent — which is fully absorbed by the body — performed as well as conventional stents at one year. Conducted at 193 sites, primarily in the United States, the ABSORB trial enrolled about 2,000 people with coronary artery disease.

The Society of Angiography and Cardiac Interventions (SCAI) issued a statement finding these initial data encouraging and that it looks forward to more long-term data over the next three to four years that will detail the benefits of this technology in participating patients. Although not yet commercially available in the United States, currently Absorb is available in more than 100 countries worldwide.

Last week, the U.S. Food and Drug Administration (FDA) approved Synergy, the first stent with a bioabsorbable polymer. Synergy’s drug coating and polymer are absorbed shortly after drug elution is complete at three months, leaving only the metal stent platform behind. This FDA approval is based on data from the EVOLVE II study, which showed Synergy performed as well as conventional stents at one year.

“These two new stents represent a new generation of stent technology. Both treat heart artery blockages like conventional stents, but are revolutionary in that they eliminate permanent stent components that occasionally cause long-term problems,” said SCAI Secretary Kirk Garratt, M.D., FSCAI. “These innovations highlight the interventional cardiology community’s continuous efforts to advance treatments that save lives and improve the quality of life for patients with cardiovascular disease.”

“Our goal is to ensure patients have the right treatment, at the right time,” said SCAI President James C. Blankenship, M.D., FSCAI. “Innovative technologies like bioabsorbable stents provide us with a wider array of options so we can offer patients the best possible treatment for their condition. We expect both stents will improve long-term outcomes for patients and reduce costs of treating coronary artery disease.”

For more information:

Related Content

Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Overlay Init